ELI LILLY Aktie

 

Eli Lilly (LLY) closed at $1 in the latest trading session, marking a -1.19% move from the prior day....

Die bekannte Wachstumsinvestorin Cathie Wood nutzt Kursrückgänge erneut für gezielte Zukäufe. Nachdem Ark Invest mehrere Handelstage überwiegend auf der Verkäuferseite stand, griff das Woods Investmenthaus am Mittwoch wieder bei ausgewählten Aktien zu. Besonders ins Auge fallen dabei die Käufe von Eli Lilly, Block und Coinbase – drei Unternehmen, die sich derzeit in sehr unterschiedlichen Phasen […] The post Star-Investorin Cathie Wood: Welche Aktien kauft sie jetzt? first appeared on sharedeals.de....

Johnson & Johnson has no plans to enter the booming obesity market, opting instead to focus on diseases such as cancer, CEO Joaquin Duato said in an interview for an upcoming episode of The David Rubenstein Show: Peer to Peer Conversations. The comments set J&J apart from many of its rivals that are trying to develop or acquire obesity medicines following blockbuster weight-loss drugs from Eli Lilly & Co. and Novo Nordisk. (Source: Bloomberg)...

These two healthcare leaders have a long history of competing against one another....

A new survey shows 10% of employers may drop GLP-1 coverage in 2027, raising fresh questions about demand for Lilly's Zepbound and Foundayo....

Novo Nordisk CEO Mike Doustdar said the company plans to soon seek approval from Chinese regulators for its weight-loss pill Wegovy, aiming to catch up with Eli Lilly and Company (LLY.US) in the China market.Doustdar said oral Wegovy data will be submitted within the coming months to seek regulatory approval, and competition fro......

Eli Lilly has experienced robust growth, but investors may be thinking twice about the stock due to its high valuation....

Mit einem einzigen Satz bringt ein Boehringer-Manager die Lage auf den Punkt. Während die USA Milliarden in Forschung und Industrie locken, diskutiert Deutschland über neue Belastungen. Warum Eli Lilly und Boehringer mehr über den Zustand des Standorts verraten als jede Konjunkturstatistik....

Die Aktie von Eli Lilly konnte in der vergangenen Woche ein neues Allzeithoch erklimmen und unterstreicht damit die außergewöhnliche Marktstellung des Unternehmens. Trotz des hohen Bewertungsniveaus sehen viele Investoren weiterhin erhebliches Potenzial, da der Konzern von langfristigen Entwicklungen im Gesundheitswesen profitiert. Einzigartiges Wachstumsmodell im Markt für Stoffwechselerkrankungen Eli Lilly entwickelt sich zunehmend zur führenden globalen […] The post Eli Lilly-Aktie: Warum Pharma-Anleger auf sie setzen first appeared on sharedeals.de....

Eli Lilly is winning the GLP-1 race right now, but it isn't resting on its laurels....

INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) announced positive results from the Phase 3 BRUIN CLL-322 clinical trial evaluating Jaypirca (pirtobrutinib), a non-covalent Bruton tyrosine kinase......

INDIANAPOLIS, June 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data from the Phase 1 AJX-101 study showing that its investigational type II JAK2 inhibitor (AJ1-11095) demonstrated an encouraging safety profile and promising clinical activity in patients......

Drugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate....

In the closing of the recent trading day, Eli Lilly (LLY) stood at $1, denoting a -2.41% move from the preceding trading day....

The pharmaceutical company's flagship anti-obesity drug continues to bolster its efficacy and tolerability arguments....

Eli Lilly, Parker-Hannifin, and Microsoft all have grown their dividend by 50% or more over the past five years, but still have plenty of room for dividend growth....

NEW BRUNSWICK (dpa-AFX) - This week, the biotech sector saw a surge of FDA, EU, and China approvals spanning oncology, dermatology, autoimmune and rare disease indications. Strategic acquisitions ......

NEW BRUNSWICK (dpa-AFX) - This week, the biotech sector saw a surge of FDA, EU, and China approvals spanning oncology, dermatology, autoimmune and rare disease indications. Strategic acquisitions ......

Eli Lilly (NYSE:LLY) is the stock everyone wants to own right now, a $1.02 trillion obesity juggernaut that has ripped 20.9% higher in a single month on the back of the GLP-1 mania. But here's what you should actually be watching. The Hot Ticker Is a Two-Drug Bet at a Trillion-Dollar Price Strip away the ... Forget Eli Lilly and Company: As June Volatility Rocks High-Flyers, This Stock Is a No-Brainer Buy...

Eli Lilly and American Express are top picks on CNBC's Halftime Report Final Trades. Live Nation is on the verge of a new 52-week high. Importance Rank:  1 read more...